Experimental oncology最新文献

{"title":"ANALYSIS OF FACTORS INFLUENCING TREATMENT OUTCOMES OF UTERINE SARCOMAS.","authors":"S S Davydiuk, A Y Kryzhanivska","doi":"10.15407/exp-oncology.2025.01.083","DOIUrl":"10.15407/exp-oncology.2025.01.083","url":null,"abstract":"<p><strong>Background: </strong>Uterine sarcoma (US) is a rare type of tumor characterized by aggressive clinical behavior and high recurrence rate. Its histopathological heterogeneity has led to a lack of consensus regarding risk factors that could guide the selection of optimal treatment strategies for this pathology.</p><p><strong>Aim: </strong>To investigate the factors influencing treatment outcomes of US.</p><p><strong>Materials and methods: </strong>We conducted a retrospective analysis of the treatment outcomes of 107 women diagnosed with stage I-II US from 2010 to 2023. The follow-up period ranged from 1.0 to 156.0 months. Kaplan - Meier survival curves were used for the analysis of overall survival (OS) and recurrence-free survival (RFS) rates. The correlation between the studied parameters was analyzed including relative risk (odds ratio, OR) and correlation coefficient.</p><p><strong>Results: </strong>The assessment of OR allowed us to identify the following prognostic factors with a negative impact on the 5-year OS and RFS of patients with US: differentiation grade G3, necrotic areas in tumor tissue, lymphovascular invasion, high mitotic activity (11 or more mitoses per 10 HPF), nuclear atypia 4+, negative ER and PR statuses, and high Ki-67 expression.</p><p><strong>Conclusions: </strong>Survival of patients with US depends on tumor grade, necrosis, and lymphovascular invasion of tumor tissue; mitotic activity and nuclear atypia; ER and PR statuses; and the level of Ki67 expression.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"83-90"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFECTS OF SARS-COV-2 SPIKE PROTEIN ON THE GROWTH AND PHENOTYPE OF MDA-MB-231 AND MCF-7 BREAST CANCER CELLS AND THEIR SENSITIVITY TO RADIATION-INDUCED APOPTOSIS.","authors":"V Brichenko, L Shlapatska, M Zavelevich, L Zvarych, V Panchenko, O Lyaskivska, O Skachkova, N Golyarnik, I Abramenko, L Buchynska, A Chumak","doi":"10.15407/exp-oncology.2025.01.024","DOIUrl":"10.15407/exp-oncology.2025.01.024","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus infection caused by SARS-Cov-2 virus, in addition to the development of severe acute respiratory syndrome, is responsible for the development of a multiple organ dysfunction syndrome. An important aspect is its relationship with cancer. The data from clinical and experimental studies are contradictory. Thus, further studies are needed to elaborate on the potential effects of SARS-Cov-2 on cancer cells.</p><p><strong>Aim: </strong>To study the effect of SARS-Cov-2 spike protein (SP) on the survival, phenotype, and sensitivity to radiation-induced apoptosis of breast cancer (BC) cell lines of different molecular subtype (MDA-MB-231 and MCF-7).</p><p><strong>Materials and methods: </strong>The effects of SARS-Cov-2 SP on MDA-MB-231 and MCF-7 cells were assessed using the cell proliferation assay and flow cytometry (Ki-67, CD44, CD133, CD105, CD90, CD10, CD5, CD19, and p53). The sensitivity to radiationinduced apoptosis was evaluated by 7-amino-actinomycin D and propidium iodide staining.</p><p><strong>Results: </strong>We did not find any significant short-term effect of SP on the proliferative activity of both studied cell lines. The phenotype of MDA-MB-231 cells cultured with SP changed toward a decrease in CD105+CD90+ and CD105+CD90- subpopulations (p < 0.0001). The p53 expression increased both in SP-treated MDA-MB-231 and MCF-7 cells. The sensitivity of SP-treated MDA-MB-231 and MCF-7 cells to radiation-induced apoptosis, although insignificantly, increased. Apoptosis in irradiated MDA-MB-231 cells was accompanied by a two-fold increase in the fluorescence intensity of p53 in SP-treated MDA-MB-231 cells. In both irradiated cultures, a significant increase in the percent of cells in S-phase after SP treatment was observed compared to SP-untreated cells.</p><p><strong>Conclusion: </strong>Since most vaccines are based on SP expression, the obtained data might have a certain significance in the study of the effect of anti-SARS-Cov-2 vaccination on tumor growth and the sensitivity of cancer cells to cytoreduction therapies.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"24-33"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ERRATUM FOR CYSTECTOMY IN METASTATIC BLADDER CANCER: FEASIBILITY, SAFETY AND OUTCOMES PUBLISHED IN EXP ONCOL 2024;46(4).","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cystectomy in Metastatic Bladder Cancer: Feasibility, Safety and Outcomes Hrechko B, Voylenko O, Pikul M, Vitruk U, Stakhovsky O, Kononenko O, Semko S, Koshel D, Tymoshenko A, Buyvol O, Stakhovsky E. Exp Oncol. 2024;46(4):345-350 DOI: https://doi.org/10.15407/exp-oncology.2024.04.345.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"124"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IN VITRO ASSESSMENT OF REVERSIBLE AND METABOLISM-DEPENDENT INHIBITORY EFFECTS OF PROPOXAZEPAM ON CYP2C8 ACTIVITY.","authors":"М Golovenko, I Valivodz, A Reder, V Larionov","doi":"10.15407/exp-oncology.2025.01.051","DOIUrl":"10.15407/exp-oncology.2025.01.051","url":null,"abstract":"<p><strong>Background: </strong>In oncology, drug-drug interactions (DDIs) are particularly relevant due to the complex medication regimens of cancer patients. These patients often require multiple drugs to manage both their disease and treatment-related side effects. Evaluating potential DDIs via the inhibition of CYP enzymes is crucial in drug discovery. This study aimed to assess the effect of propoxazepam on CYP2C8 activity in vitro by amodiaquine N-deethylation in human liver microsomes and to predict the likelihood of DDI through CYP activity reduction.</p><p><strong>Materials and methods: </strong>Amodiaquine Ndeethylation was used as a marker of CYP2C8 activity. The positive controls included montelukast (1 μM) for rever sible inhibition and gemfibrozil O-glucuronide (40 μM) for metabolism-dependent inhibition. Propoxazepam was tested in both reversible and metabolism-dependent inhibition conditions being added with the substrate or pre-incubated with microsomes and NADPH, respectively. The metabolite formation was quantified by LC-MS/MS in a multiple reaction monitoring mode using the electrospray ionization technique.</p><p><strong>Results: </strong>Propoxazepam inhibited CYP2C8 activity in a concentration-dependent manner, with IC50 values of 20.5 ± 2.2 μM for reversible inhibition and 23.1 ± 3.2 μM for metabolism-dependent inhibition. Positive controls montelukast and gemfibrozil O-glucuronide showed expected inhibition (4.4% and 12.2% of control, respectively). Propoxazepam showed low binding to microsomal protein under the experimental conditions.</p><p><strong>Conclusion: </strong>Based on the indicators used (Ki, IC50, IC50 shift, and [I]/Ki ratios), propoxazepam is not expected to be a significant CYP2C8 inhibitor in vitro.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"51-59"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"СIRCULATING MIRNAS AS PREDICTIVE MARKERS FOR LINE I AND II NEOADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER.","authors":"T V Borikun, V Bazas, T Zadvornyi, I Karacharova, Yu Lytovchenko, N Lukianova","doi":"10.15407/exp-oncology.2025.01.016","DOIUrl":"10.15407/exp-oncology.2025.01.016","url":null,"abstract":"<p><strong>Background: </strong>miRNAs have emerged as promising biomarkers for breast cancer, particularly in predicting treatment response and prognosis. Their ability to regulate gene expression and their presence in various bodily fluids make them valuable tools for personalized medicine.</p><p><strong>Materials and methods: </strong>The study was based on a retrospective analysis of the results of the examination, treatment, and survival of 94 patients with stage II-III triple-negative breast cancer (TNBC) who underwent treatment at the Kyiv City Clinical Oncology Center during 2013-2017. miRNA expressions in blood serum were estimated using the real-time RT-PCR.</p><p><strong>Results: </strong>The elevated levels of miR-21, -155, -199a, and -200b (p < 0.05) were linked to metastasis to regional lymph nodes, while miR-373 and -126 expression levels were associated with the tumor stage (r = 0.55 and 0.57, respectively, p < 0.05). The higher serum levels of miR-21 (> 5.4, p < 0.05), -125b (> 6.0, p < 0.05) and the lower miR-205 levels (< 2.0, p < 0.05) were associated with the poorer response to line I and II neoadjuvant chemotherapy. The serum levels of miR-21, -125b, -126, -199a, -200b, -205, and -373 were found to correlate with the overall and recurrence-free survivals in TNBC patients.</p><p><strong>Conclusions: </strong>These findings suggest that miRNA-based biomarkers may have the potential as prognostic and predictive tools in TNBC, aiding in personalized treatment strategies.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"16-23"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHOLANGIOCARCINOMA IN TWIN PREGNANCY: A CASE REPORT.","authors":"V L Dronova, O I Dronov, S A Lyalkin, O M Mokryk, R S Teslyuk","doi":"10.15407/exp-oncology.2025.01.096","DOIUrl":"10.15407/exp-oncology.2025.01.096","url":null,"abstract":"<p><p>Cholangiocarcinoma during pregnancy is a very rare condition. We present the case of a 35-year-old pregnant woman with intrahepatic cholangiocarcinoma. To our knowledge, this is the first case of cholangiocarcinoma in a patient with twin pregnancy. At 25 weeks of gestation, surgical intervention was performed: right-sided hemihepatectomy, lymphadenectomy D3, and diaphragmatic peritoneumectomy on the right side. At 33 weeks of pregnancy, a cesarean section was performed. Currently, the patient is receiving chemotherapy. A multidisciplinary approach should be a standard workup in making decisions regarding the treatment strategy for a pregnant patient with a cancer diagnosis.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CORRELATION OF APOPTOSIS MARKERS LEVELS WITH THE DEVELOPMENT OF HEPATIC FAILURE IN MALIGNANT OBSTRUCTIVE JAUNDICE.","authors":"O Dronov, I Kovalska, L Roshchyna, L Levchenko, D Vlasenko","doi":"10.15407/exp-oncology.2025.01.068","DOIUrl":"10.15407/exp-oncology.2025.01.068","url":null,"abstract":"<p><p>Obstructive jaundice (OJ) is a common diagnosis in everyday clinical practice, which requires a thorough understanding of pathophysiological changes occurring in the liver to plan ongoing treatment and predict its effectiveness in the postoperative period. The study aimed to determine the dynamics of changes in the levels of apoptosis markers (caspase-3 and BCL-2) at the time of preoperative biliary decompression (PBD) and major surgery depending on the severity of the hepatic failure (HF) and to evaluate their correlation with the severity grade of HF in patients with malignant obstructive jaundice (MOJ).</p><p><strong>Materials and methods: </strong>The study included 104 patients with MOJ who underwent PBD. All patients were diagnosed with HF of moderate severity (n = 65) or severe HF (n = 39). During PBD and main surgical intervention, the levels of caspase-3 and BCL-2 were determined in blood serum and bile by the Sandwich-ELISA method.</p><p><strong>Results: </strong>The values of apoptosis markers in patients with moderate and severe HF were significantly different at the time of PBD and major surgery (p < 0.001). PBD significantly reduced the levels of caspase-3 and increased the levels of BCL-2 in sera of patients with MOJ and HF, which was confirmed by further intraoperative values of the indicators, p < 0.001. Imbalance of serum caspase-3 (R2 Nagelkerke = 0.553, p = 0.013) and BCL-2 (R2 Nagelkerke = 0.327, p = 0.003) levels was associated with severe HF.</p><p><strong>Conclusions: </strong>The indicators of apoptosis after PBD can serve as additional markers of the effectiveness of a patient's treatment in the preoperative period and can be included in the diagnostic and therapeutic algorithm for patients with MOJ.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"68-75"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ATYPICAL BRAF MUTATIONS IN HAIRY CELL LEUKEMIA: DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS.","authors":"S E Langabeer, G Crotty, C L Bacon","doi":"10.15407/exp-oncology.2025.01.122","DOIUrl":"https://doi.org/10.15407/exp-oncology.2025.01.122","url":null,"abstract":"<p><p>Atypical BRAF Mutations in Hairy Cell Leukemia: Diagnostic and Therapeutic Considerations.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"122-123"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MODULATION OF PD-L1 EXPRESSION IN PROSTATE CANCER CELLS THROUGH ANDROGEN RECEPTOR INHIBITION DIFFERS DEPENDING ON RECEPTOR STATUS.","authors":"N Najafzade, E Ozgur, S B Gazioglu, E E Yoruker, U Gezer","doi":"10.15407/exp-oncology.2025.01.060","DOIUrl":"10.15407/exp-oncology.2025.01.060","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint blockade (ICB) therapy targeting the PD-1/PD-L1 axis results in poor outcomes in prostate cancer (PCa). PD-L1, the most commonly used predictive marker for the efficacy of PD-1/PD-L1-targeted immunotherapy, appears to be rarely or at low levels expressed in primary androgen-responsive PCa tumors, with higher levels in advanced PCa. PD-L1 expression has not yet been studied regarding the androgen receptor (AR) status.</p><p><strong>Materials and methods: </strong>We investigated the effect of hormone stimulation by dihydrotestosterone (DHT) and AR inhibition by enzalutamide on PD-L1 expression in LNCaP and LNCaP-AR+ cells, the latter overexpressing AR. Cells were grown for 24 h under hormone-free conditions and then for 24 h in the presence of DHT (10 nM) and/or enzalutamide (10 μM). Cell viability was assessed by Annexin V and propidium iodi de staining. PD-L1 expression was determined semiquantitatively at the mRNA level. ANOVA and independent t-tests were used to compare experimental results between different treatment modalities.</p><p><strong>Results: </strong>DHT treatment induced some degree of apoptosis in AR-overexpressing LNCaP-AR + cells, but not in parental LNCaP cells. We found low basal expression of PD-L1 in both cell lines, with 2.7-fold higher levels in LNCaP-AR+ cells. DHT treatment increased PD-L1 expression by approximately three-fold in LNCaP cells, while in enzalutamide-treated cells, the expression was lower than the basal level. In LNCaP cells treated concomitantly with DHT and enzalutamide, AR inhibition reduced DHT-induced PD-L1, suggesting an androgen-dependent expression of PD-L1. Unlike in LNCaP cells, androgen stimulation did not increase PD-L1 expression in LNCaP-AR+ cells, and enzalutamide did not affect PD-L1 expression either.</p><p><strong>Conclusion: </strong>Our data reveal that PD-L1 is expressed in an AR-dependent manner in PCa cells, and its expression in AR-overexpressing cells is not modulated by receptor inhibition.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"60-67"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IMMUNOHISTOCHEMICAL STUDY OF CD44 AND OCT3/4 EXPRESSION IN COLORECTAL CANCER SAMPLES OF IRAQI PATIENTS.","authors":"Noah A MahmoodМахмуд, Firas S Salah, Zaynab S Abdulghany, Khansaa R Al-Saadi, Hayder A Hassoon, Tiba H Jaafar, Rasha A Hussein","doi":"10.15407/exp-oncology.2025.01.044","DOIUrl":"10.15407/exp-oncology.2025.01.044","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is one of the most common cancer types diagnosed globally with high rates of morbidity and mortality. Several biomarkers are associated with cancer stem cells present in various solid tumors, including CRC.</p><p><strong>Aim: </strong>This study aimed to investigate the expression of CD44 and OCT3/4 cancer stem cell markers in samples of CRC biopsies and benign colon tumors of Iraqi patients using the immunohistochemical (IHC) technique.</p><p><strong>Materials and methods: </strong>The IHC analysis was used to determine CD44 and OCT3/4 expression levels in tissue samples of 42 CRC cases and 18 benign neoplasms.</p><p><strong>Results: </strong>The findings revealed a significant increase in high expression levels of CD44 in CRC cases (81%) vs 23% in benign tumor tissue samples. Similarly, a significant rise in OCT3/4 expression was observed in CRC cases (66%) compared to benign tumors (29%). The expression levels of CD44 and OCT3/4 were significantly associated with the CRC stages.</p><p><strong>Conclusion: </strong>Our data indicated that CD44 and OCT3/4 may play a role in CRC progression.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"47 1","pages":"44-50"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}